A. Płonowski

B. Baranowska, E. Wasilewska-Dziubińska, A. Płonowski, 1999, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone.

A. Schally, Z. Rékási, T. Czompoly, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Are μ-opioid receptors involved in the control of endothelin-1 release from the pituitary gland in normal and dehydrated rats?

B. Baranowska, A. Płonowski, B. Woźniewicz, 1997, Regulatory Peptides.

Impaired response of atrial natriuretic peptide to acute water load in obesity and in anorexia nervosa.

B. Baranowska, E. Wasilewska-Dziubińska, A. Płonowski, 1995, European journal of endocrinology.

Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors

A. Fanjul, C. Zopf, Christopher Mcbride, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.

A. Schally, A. Nagy, A. Płonowski, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Regulation of prostate‐specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone‐releasing hormone and vasoactive intestinal peptide

A. Schally, Z. Rékási, T. Czompoly, 2001, The Prostate.

Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.

A. Schally, F. Hébert, H. Kiaris, 2000, Cancer research.

Targeted cytotoxic analog of luteinizing hormone‐releasing hormone AN‐207 inhibits the growth of PC‐82 human prostate cancer in nude mice

A. Schally, K. Groot, M. Koppán, 1999 .

Correlation between 21 amino acid endothelin, intrafollicular steroids and follicle size in stimulated cycles.

B. Baranowska, A. Płonowski, M. Borowiec, 1999, Human reproduction.

Effects of PACAP and VIP on Adrenal Progesterone Release

B. Baranowska, E. Wasilewska-Dziubińska, A. Płonowski, 1996, Annals of the New York Academy of Sciences.

Inhibition of proliferation of PC‐3 human prostate cancer by antagonists of growth hormone–releasing hormone: Lack of correlation with the levels of serum IGF‐I and expression of tumoral IGF‐II and vascular endothelial growth factor

A. Schally, M. Krupa, F. Hébert, 2002, The Prostate.

Discovery and characterization of an inhibitor of glucosylceramide synthase.

K. Ogilvie, J. Nuss, S. Richards, 2012, Journal of medicinal chemistry.

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

K. Yamaguchi, D. J. Matthews, F. Yakes, 2015, Molecular Cancer Therapeutics.

Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors

A. Schally, M. Krupa, K. Groot, 2002, Regulatory Peptides.

Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers

A. Schally, M. Krupa, G. Halmos, 2002, Peptides.

Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways

A. Schally, K. Groot, Z. Rékási, 2001, Peptides.

Time-dependent inhibition of PHD2

Lihong Shi, C. Grimshaw, J. Ermolieff, 2017, Bioscience reports.

Discovery of Highly Potent Liver X Receptor β Agonists

A. D. Rodrigues, P. Sleph, T. Kirchgessner, 2016, ACS medicinal chemistry letters.

Neuropeptide Y, galanin, and leptin release in obese women and in women with anorexia nervosa.

B. Baranowska, E. Wasilewska-Dziubińska, B Baranowska, 1997, Metabolism: clinical and experimental.

Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ.

T. Kirchgessner, M. Nanao, I. Schulman, 2015, Bioorganic & medicinal chemistry letters.

Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.

A. Schally, M. Koppán, J. M. Arencibia, 1998, Cancer research.

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.

A. Schally, K. Groot, M. Koppán, 1999, The Prostate.

Prostate Cancer in Rats at Nontoxic Doses Growth of Androgen-independent Dunning R-3327-AT1 Targeted Cytotoxic Analogue of Somatostatin AN-238 Inhibits Updated

Andrew, J. M. Arencibia, A. Nagy, 2006 .

Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1.

J. Lawson, Christopher Mcbride, P. Farrell, 2016, Bioorganic & medicinal chemistry letters.

Inhibition of the UCI‐107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN‐238

A. Schally, M. Koppán, J. M. Arencibia, 2001, Cancer.

Potentiation of the inhibitory effect of growth hormone‐releasing hormone antagonists on PC‐3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

A. Schally, K. Groot, Z. Rékási, 2000, The Prostate.

Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK‐ES‐1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone‐releasing hormone

A. Schally, M. Krupa, K. Groot, 2002, Cancer.

Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 2.

J. Lawson, Christopher Mcbride, P. Farrell, 2016, Bioorganic & medicinal chemistry letters.

Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215

A. Bajo, A. Schally, K. Groot, 2002, British Journal of Cancer.